Carregando...
Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
OBJECTIVE: Acquired T790M mutations account for 50%–60% of tyrosine kinase inhibitor (TKI)-resistant mechanisms in EGFR mutation-positive (m+) non-small-cell lung cancer (NSCLC) patients, and re-biopsy is recommended to detect these mutations. We investigated the re-biopsy status and the T790M incid...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Principais autores: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6208793/ https://ncbi.nlm.nih.gov/pubmed/30464499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S174075 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|